scholarly journals Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy

2016 ◽  
Vol 82 (1) ◽  
pp. 238-248 ◽  
Author(s):  
Monia Donati ◽  
Anita Conforti ◽  
Maria Carmela Lenti ◽  
Annalisa Capuano ◽  
Oscar Bortolami ◽  
...  
Keyword(s):  
Liver Injury ◽  
Case Control Study ◽  
Case Control ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Control Study

scholarly journals Acute and clinically relevant drug-induced liver injury: a population based case-control study

2004 ◽  
Vol 58 (1) ◽  
pp. 71-80 ◽  
Author(s):  
Francisco J. de Abajo ◽  
Dolores Montero ◽  
Mariano Madurga ◽  
Luis A. Garcia Rodriguez
Keyword(s):  
Liver Injury ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Control Study

scholarly journals Association between genetic polymorphisms of NRF2, KEAP1, MAFF, MAFK and anti-tuberculosis drug-induced liver injury: a nested case-control study

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Shixian Chen ◽  
Hongqiu Pan ◽  
Yongzhong Chen ◽  
Lihuan Lu ◽  
Xiaomin He ◽  
...  
Keyword(s):  
Liver Injury ◽  
Signaling Pathway ◽  
Genetic Polymorphisms ◽  
Case Control Study ◽  
Case Control ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Tb Treatment ◽  
Nested Case Control ◽  
Control Study

Abstract Reactive metabolites of anti-tuberculosis (anti-TB) drugs can result in excessive reactive oxygen species (ROS), which are responsible for drug-induced liver injury. The nuclear factor erythroid 2-related factor 2 (Nrf2) - antioxidant response elements (ARE) (Nrf2-ARE) signaling pathway plays a crucial role in protecting liver cells from ROS, inducing enzymes such as phase II metabolizing enzymes and antioxidant enzymes. Based on a Chinese anti-TB treatment cohort, a nested case-control study was performed to explore the association between 13 tag single-nucleotide polymorphisms (tagSNPs) in the NRF2, KEAP1, MAFF, MAFK genes in Nrf2-ARE signaling pathway and the risk of anti-TB drug-induced liver injury (ATLI) in 314 cases and 628 controls. Conditional logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) after adjusting weight and usage of hepatoprotectant. Patients carrying the TC genotype at rs4243387 or haplotype C-C (rs2001350-rs6726395) in NRF2 were at an increased risk of ATLI (adjusted OR = 1.362, 95% CI: 1.017–1.824, P = 0.038; adjusted OR = 2.503, 95% CI: 1.273–4.921, P = 0.008, respectively), whereas patients carrying TC genotype at rs2267373 or haplotype C-G-C (rs2267373-rs4444637-rs4821767) in MAFF were at a reduced risk of ATLI (adjusted OR = 0.712, 95% CI: 0.532–0.953, P = 0.022; adjusted OR = 0.753, 95% CI: 0.587–0.965, P = 0.025, respectively). Subgroup analysis also detected a significant association between multiple tagSNPs (rs4821767 and rs4444637 in MAFF, rs4720833 in MAFK) and specific clinical patterns of liver injury under different genetic models. This study shows that genetic polymorphisms of NRF2, MAFF and MAFK may contribute to the susceptibility to ATLI in the Chinese anti-TB treatment population.

Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care

2004 ◽  
Vol 18 (2) ◽  
pp. 201-206 ◽  
Author(s):  
I. Lacroix ◽  
M. Lapeyre-Mestre ◽  
H. Bagheri ◽  
A. Pathak ◽  
J.L. Montastruc ◽  
...  
Keyword(s):  
Primary Care ◽  
Liver Injury ◽  
Case Control Study ◽  
Case Control ◽  
Drug Induced ◽  
Inflammatory Drug ◽  
Drug Induced Liver Injury ◽  
Anti Inflammatory ◽  
Control Study

scholarly journals Genetic polymorphisms of UGT1A1 and susceptibility to anti-tuberculosis drug-induced liver: A RUCAM-based case–control study

2018 ◽  
Vol 32 ◽  
pp. 205873841881628 ◽  
Author(s):  
Bilin Tao ◽  
Shixian Chen ◽  
Guancheng Lin ◽  
Miaomiao Yang ◽  
Lihuan Lu ◽  
...  
Keyword(s):  
Liver Injury ◽  
Genetic Polymorphisms ◽  
Case Control Study ◽  
Causality Assessment ◽  
Conditional Logistic Regression ◽  
Assessment Method ◽  
Case Control ◽  
Bile Acid Metabolism ◽  
Drug Induced ◽  
Control Study

Uridine 5’-diphospho-glucuronosyl-transferase 1A1 (UGT1A1) plays an important role in the biliary excretion of bilirubin, suggesting genetic polymorphisms of UGT1A1 may have an impact on bile acid metabolism, which may be related to the development of anti-tuberculosis drug-induced liver injury (ATLI). This study explores the associations between genetic polymorphisms of UGT1A1 and ATLI in a Chinese anti-tuberculosis population. A 1:2 matched case–control study was conducted among 290 ATLI cases and 580 controls, of which causality assessment of ATLI cases was based on the updated Roussel Uclaf Causality Assessment Method (RUCAM). Conditional logistic regression was applied to calculate odds ratio (OR) and 95% confidence intervals (CIs), with weight and use of hepatoprotectant as covariates. The Bonferroni correction was used to adjust P values for multiple testing. Compared with those carrying rs6719561 TT genotype, patients with TC genotype had lower risk of ATLI (adjusted OR = 0.723, 95% CI: 0.531–0.985, P = 0.040). The haplotype TAG (rs3755319-rs2003569-rs4148323) could marginally significantly increase the risk of ATLI (adjusted OR = 5.071, 95% CI: 1.007–25.531, P = 0.049), while haplotype TC (rs4148329-rs6719561) could reduce the risk of ATLI (adjusted OR = 0.719, 95% CI: 0.527–0.982, P = 0.038). Patients with polymorphisms at rs4148328 or rs3755319 were at a reduced risk of moderate and severe liver injury under different genetic models. Based on this case–control study, genetic polymorphisms of UGT1A1 may be associated with susceptibility to ATLI in the Chinese anti-tuberculosis population.

scholarly journals Incidence, characteristic and risk factors of drug-induced liver injury in hospitalized patients: a matched case-control study

2021 ◽  
Author(s):  
Xianghao Kong ◽  
Daihong Guo ◽  
Siyuan Liu ◽  
Yu Zhu ◽  
Chengxuan Yu
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Liver Disease ◽  
Case Control Study ◽  
Case Control ◽  
Hospitalized Patients ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Surgical History ◽  
Control Study

Abstract: Aims: The diagnosis of drug-induced liver injury (DILI) is relatively complex, involving a wide variety of drugs. The purpose of this study is to use algorithms to quickly screen DILI patients, count incidence rates and find risk factors. Methods: The Adverse Drug Events Active Surveillance and Assessment System-2 was used to extract the data of hospitalized patients in 2019 according to the set standards, then the RUCAM was used to evaluate patients who meet the standards. A retrospective case-control study was conducted according to suspected drugs, length of hospital stay, height and weight matched controls, and logistic regression was used to find risk factors. Results: Among the 156,570 hospitalized patients, 480 patients (499 cases) of DILI were confirmed, and the incidence of DILI was 0.32%. Anti-infective agents, antineoplastic agents, non-steroidal anti-inflammatory drugs (NASIDs) were the major category of causative drugs causing DILI, and the highest incidence of DILI caused by agent of voriconazole. The latency period and hospital stay of patients with cholestasis was relatively long. Patients with hyperlipidemia (AOR: 1.884), cardiovascular disease (AOR: 1.465), pre-existing liver disease (AOR: 1.827) and surgical history (AOR: 1.312) were likely to be risk factors for DILI. Conclusions: The incidence of DILI in hospitalized patients was uncommon (0.32%), and its pathogenic drugs were widely distributed. LiverTox’s information could assist in the diagnosis of DILI. The incidence of DILI in many drugs was seriously underestimated. It is recommended to focus on patients with hyperlipidemia, cardiovascular disease, pre-existing liver disease, and surgical history.

Sign in / Sign up

Export Citation Format

Share Document